Cengiz S Askun

Dr. Cengiz S Askun


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MMMelike Mut
Melike Mut
HZHatice Yağmur Zengin
Hatice Yağmur Zengin
AAAynur Azizova
Aynur Azizova
CACengiz S Askun
Cengiz S Askun
DSDavid Schiff
David Schiff
FSFigen Soylemezoglu
Figen Soylemezoglu
Background and Objectives: This study aims to evaluate the overall survival benefits of repeat resection in patients with recurrent glioblastoma, IDH-wildtype (rGBM), and to identify factors for long-term survival, including the role of clinical, radiological, and molecular parameters. Methods: This longitudinal matched case-control study included 60 patients with rGBM divided into two groups: one surgery (n = 30) and repeat resection (n = 30). The baseline characteristics, preoperative and postoperative volumes, and molecular markers were assessed. Survival analyses were conducted using the Log-rank test, and associated factors with long-term survival were identified in the repeat resection cohort. Results: The patients who underwent repeat resection had a significantly longer median survival of 23.9 months compared to 9.2 months in the one-surgery group (p < 0.001). Preoperative tumor volume was found to correlate with postoperative residual volume in repeat resections. The patients with no residual contrast-enhancing tumor volume (0 cm3) after repeat resection had a median survival of 19.33 months, while those with any residual volume had a median survival of 10.13 months. The patients with lower KPS (≤70) and GCS (≤13) scores at the time of the repeat resection tended to have shorter survival, underscoring the potential clinical relevance of functional status when evaluating surgical candidacy. Conclusions: Complete repeat resection may improve overall survival in patients with recurrent IDH-wildtype GBM and should be considered earlier as a therapeutic option rather than a diagnostic or salvage procedure. Early surgical intervention, before declines in the KPS and GCS or tumor volumes become unmanageable, may lead to better outcomes. Further studies with larger cohorts are needed to confirm these findings.

20 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MMMelike Mut
Melike Mut
HZHatice Yağmur Zengin
Hatice Yağmur Zengin
AAAynur Azizova
Aynur Azizova
CACengiz S Askun
Cengiz S Askun
DSDavid Schiff
David Schiff
FSFigen Soylemezoglu
Figen Soylemezoglu
Background and Objectives: This study aims to evaluate the overall survival benefits of repeat resection in patients with recurrent glio-blastoma, IDH-wild type (rGBM) and to identify factors for long-term survival, including the role of clinical, radiological, and molecular parameters. Methods: This longitudinal matched case-control study included 60 patients with rGBM divided into two groups: one-surgery (n=30) and repeat resection (n=30). Baseline characteristics, preoperative and postoperative volumes, and molecular markers were assessed. Survival analyses were conducted using the Log-Rank test, and associated factors with long-term survival were identified in the repeat resection cohort. Results: Patients who underwent repeat resection had a significantly longer median survival of 23.9 months compared to 9.2 months in the one-surgery group (p < 0.001). Preoperative tumor volume was found to correlate with postoperative residual volume in repeat resections. Patients with no residual contrast-enhancing tumor vol-ume (0 cm³) after repeat resection had a mean survival of 25.0 months, while those with any residual volume had a mean survival of 9.4 months. Lower KPS (≤70) and GCS (≤13) scores were significantly associated with short-term survival, highlighting the importance of functional status at the time of repeat resection. Conclusion: Complete repeat resection may improve overall survival in patients with recurrent IDH-wildtype GBM and should be considered a therapeutic option rather than a diagnostic or salvage procedure. Early surgical inter-vention, before declines in KPS and GCS or tumor volumes become unmanageable, may lead to better out-comes. Further studies with larger cohorts are needed to confirm these findings.